Biogen Inc. BIIB NDXSPXR3KPHARMA

Q: What is the current share price of Biogen Inc. (BIIB)?

As of 2026-09-07 16:24 PDT, Biogen Inc. (BIIB) trades at $220.83 on NasdaqGS. Its 52-week range is $132.22 to $224.51.

Q: What is the market capitalisation of BIIB?

Biogen Inc. (BIIB) has a market capitalisation of $32.63B on NasdaqGS.

Q: What is the P/E ratio of BIIB?

BIIB trades at a trailing price-to-earnings (P/E) ratio of 39.22. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.63.

Q: What is the return on equity (ROE) of BIIB?

BIIB has a return on equity (ROE) of 4.58%. Its return on capital employed (ROCE) is 10.89%.

Q: Is BIIB a good stock to buy?

This page provides a data-driven analysis of Biogen Inc. (BIIB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - General · United States

https://www.biogen.com

Company Profile ↓

$220.83

+63.35% 1Y

Mkt Cap$32.63B

P/E39.22

P/B1.63

52W High$224.51

52W Low$132.22

Book Value$127.61

EPS (TTM)$5.63

Company Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Why Investors Should Care

Healthy Margins

Operating margin of 25.1% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $9.89B (+2.2% YoY); net profit $1.29B.
Trailing 12 Months Year-on-year growth — revenue +3.4%, earnings -84.8%.
5-Year Trend Long-term compounding — revenue CAGR 6.5%, profit CAGR 4.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	6.52%
1 Year:	3.40%

Compounded Profit Growth

5 Years:	4.00%
1 Year:	-84.80%

Stock Price Performance

1 Year:	+63.35%
6 Months:	+19.45%
3 Months:	+13.05%
1 Month:	+7.05%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 96% of range

$132.22 $224.51

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)57.98 · Neutral

Price Performance

1M+7.05%

3M+13.05%

6M+19.45%

1Y+63.35%

Valuation vs Sector

P/E of 39.22 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

39.22

Industry PE

25.17

Forward P/E

13.31

PEG Ratio

4.97

Book Value

$127.61

Price to Book

1.63

P/S

3.06

EV/EBITDA

11.18

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

6.52%

Profit 5Y

4.00%

Revenue (YoY)

3.40%

Earnings (YoY)

-84.80%

Profitability & Returns

ROCE

10.89%

ROE

4.58%

ROA

5.21%

Profit Margin

8.32%

Op Margin

25.06%

Gross Margin

78.32%

EPS (Latest Qtr)

$2.15

EPS (TTM)

$5.63

Balance Sheet & Liquidity

Debt/Equity

0.44

Quick Ratio

0.94

Current Ratio

1.86

Debt

$8.36B

Total Assets

$29.48B

Current Assets

$9.19B

Working Capital

$5.62B

Ownership

Promoter Holding

0.19%

Chg in Prom Hold

0.00%

FII / Inst Holding

99.51%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$32.63B

Total Revenue (TTM)

$10.03B

EBITDA

$3.36B

Free Cash Flow

$1.27B

Operating Cash Flow

$2.88B

Shares Outstanding

147.75M

Gross Margin

78.32%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	BIIB Biogen Inc. NDXSPXR3KPHARMA	220.83	39.22	$32.63B	0.00%	10.89%	4.58%	6.52%	4.00%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	2.56B	2.59B	2.78B	2.84B	2.73B	2.89B	2.96B	2.87B	2.81B	3.08B	3.08B	3.31B	3.13B	3.36B	3.44B	3.53B	3.49B	3.62B	3.60B	3.67B	3.53B	3.68B	3.38B	2.85B	2.69B	2.77B	2.78B	2.53B	2.59B	2.51B	2.46B	2.46B	2.53B	2.29B	2.46B	2.47B	2.43B	2.65B	2.53B	2.48B
Gross Profit	2.24B	2.31B	2.47B	2.51B	2.41B	2.52B	2.54B	2.49B	2.43B	2.71B	2.71B	2.80B	2.69B	2.94B	2.98B	3.04B	2.89B	3.14B	3.17B	3.22B	3.08B	3.27B	2.93B	2.36B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	1.12B	1.23B	1.37B	-	1.38B	1.46B	1.43B	-	1.02B	1.20B	1.65B	-	1.53B	1.21B	1.70B	-	1.50B	1.96B	1.81B	-	1.82B	1.97B	1.09B	-	973.90M	485.70M	794.00M	610.70M	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	822.50M	927.30M	965.60M	831.60M	970.90M	1.05B	1.03B	649.20M	747.60M	862.80M	1.23B	-297.40M	1.17B	866.60M	1.44B	946.80M	1.41B	1.49B	1.55B	1.44B	1.40B	1.54B	701.50M	357.90M	410.20M	448.50M	329.20M	303.80M	1.06B	1.13B	387.90M	591.60M	-68.10M	393.40M	583.60M	388.50M	240.50M	634.80M	466.50M	319.50M
Diluted EPS	3.49	3.93	4.15	3.77	4.43	4.79	4.71	2.99	3.46	4.07	5.79	-1.40	5.54	4.18	7.15	4.73	7.15	7.85	8.39	8.08	8.08	9.59	4.46	2.32	2.69	2.99	2.22	2.06	7.24	7.84	2.67	4.07	-0.47	2.70	4.00	2.66	1.64	4.33	3.17	2.15

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	3.17B	4.10B	4.38B	4.72B	5.05B	5.52B	6.93B	9.70B	10.76B	11.45B	12.27B	13.45B	14.38B	13.44B	10.98B	10.17B	9.84B	9.68B	9.89B
Gross Profit	-	-	4.00B	4.32B	4.58B	4.97B	6.07B	8.53B	9.52B	9.97B	10.64B	11.64B	12.42B	11.64B	-	-	-	-	-
Operating Income	779.77M	1.21B	1.30B	1.25B	1.72B	1.86B	2.52B	3.97B	4.89B	5.15B	5.35B	5.89B	7.04B	4.55B	2.84B	-	-	-	-
Net Income	638.17M	783.17M	970.13M	1.01B	1.23B	1.38B	1.86B	2.93B	3.55B	3.70B	2.54B	4.43B	5.89B	4.00B	1.56B	3.05B	1.16B	1.63B	1.29B
Diluted EPS	1.99	2.65	3.35	3.94	5.04	5.76	7.81	12.37	15.34	16.93	11.92	21.58	31.42	24.80	10.40	20.87	7.97	11.18	8.79
R&D Expense	925.16M	1.07B	1.28B	1.25B	1.22B	1.33B	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	8.48B	8.55B	8.09B	9.05B	10.13B	11.86B	14.31B	19.50B	22.88B	23.65B	25.29B	27.23B	24.62B	-	24.55B	26.84B	28.05B	29.44B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.79B	6.86B	7.46B	8.97B
Cash & Equivalents	661.38M	659.66M	622.38M	581.89M	759.60M	514.54M	570.70M	602.60M	1.20B	1.31B	2.33B	1.57B	1.22B	2.91B	-	-	3.42B	1.05B	2.38B	3.01B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.34B	2.53B	2.46B	2.17B
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.14B	2.10B	1.87B	1.87B
Total Liabilities	-	-	2.65B	2.29B	2.64B	2.62B	3.17B	3.24B	3.50B	10.13B	10.75B	11.05B	12.26B	13.90B	13.93B	-	11.17B	12.05B	11.33B	11.18B
Current Liabilities	-	-	923.22M	714.94M	1.05B	912.89M	1.66B	1.76B	2.22B	2.58B	3.42B	3.37B	3.30B	4.86B	3.74B	-	3.27B	3.43B	5.53B	3.35B
Long Term Debt	-	-	-	-	1.04B	1.02B	687.40M	592.43M	580.30M	6.52B	6.51B	5.93B	5.94B	4.46B	7.43B	-	6.28B	6.79B	4.55B	6.29B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.61B	7.34B	6.63B	6.58B
Total Equity	7.16B	5.55B	5.81B	6.22B	5.40B	6.43B	6.96B	8.62B	10.81B	9.37B	12.14B	12.61B	13.04B	13.34B	10.70B	-	13.40B	14.80B	16.72B	18.26B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	167.80M	168.70M	169.52M	170.60M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	1.02B	1.56B	1.07B	1.62B	1.73B	1.88B	2.35B	2.94B	3.92B	4.59B	4.55B	6.19B	7.08B	4.23B	3.64B	1.38B	1.55B	2.88B	2.20B
Investing Cash Flow	-286.57M	-365.87M	-395.03M	345.32M	-1.65B	-950.34M	-1.60B	-1.54B	-4.55B	-2.48B	-2.96B	-2.05B	470.50M	-608.60M	-563.70M	1.58B	-4.10B	-799.20M	-1.37B
Financing Cash Flow	-733.34M	-1.23B	-724.15M	-1.78B	-319.86M	-877.48M	-716.50M	-755.90M	783.10M	-1.05B	-2.38B	-4.47B	-5.86B	-5.27B	-2.09B	-1.75B	149.30M	-683.50M	-301.90M
Capital Expenditure	-284.11M	-275.95M	-165.65M	-173.06M	-208.02M	-254.55M	-246.30M	-287.80M	-643.00M	-616.10M	-867.40M	-770.60M	-514.50M	-424.80M	-258.10M	-240.30M	-277.00M	-153.70M	-153.80M
Free Cash Flow	734.65M	1.29B	909.25M	1.45B	1.52B	1.63B	2.10B	2.65B	3.28B	3.97B	3.68B	5.42B	6.56B	3.81B	3.38B	1.14B	1.27B	2.72B	2.05B
Share Buybacks	2.99B	738.94M	751.17M	2.08B	497.98M	984.72M	400.30M	886.80M	5.00B	1.00B	1.37B	4.35B	5.87B	6.68B	1.80B	750.00M	0	0	-

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	91.3%	91.5%	90.8%	90.1%	87.6%	87.9%	88.5%	87.1%	86.7%	86.5%	86.4%	86.6%	-	-	-	-	-
Operating Margin %	24.6%	29.6%	29.6%	26.5%	34.2%	33.6%	36.3%	40.9%	45.4%	45.0%	43.6%	43.8%	49.0%	33.8%	25.9%	-	-	-	-
Net Margin %	20.1%	19.1%	22.2%	21.3%	24.5%	25.0%	26.9%	30.2%	33.0%	32.3%	20.7%	32.9%	41.0%	29.8%	14.2%	29.9%	11.8%	16.9%	13.1%
ROE %	11.5%	13.5%	15.6%	18.6%	19.2%	19.8%	21.6%	27.2%	37.8%	30.5%	20.1%	34.0%	44.1%	37.4%	-	22.7%	7.8%	9.8%	7.1%
ROCE %	-	16.1%	16.5%	17.7%	21.2%	21.9%	24.9%	32.8%	28.9%	26.5%	26.4%	26.8%	31.5%	21.8%	-	-	-	-	-

Shareholding Pattern

Insiders

0.19%

Institutions

99.51%

Public Float

99.70%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	FMR, LLC	12.33%	18.22M	$3.98B
2	Blackrock Inc.	10.82%	15.99M	$3.49B
3	Primecap Management Company	10.26%	15.15M	$3.31B
4	Vanguard Capital Management LLC	6.53%	9.65M	$2.11B
5	State Street Corporation	4.97%	7.34M	$1.60B
6	Vanguard Portfolio Management LLC	4.47%	6.60M	$1.44B
7	Geode Capital Management, LLC	3.01%	4.45M	$972.17M
8	Wellington Management Group, LLP	2.11%	3.12M	$681.17M
9	NORGES BANK	1.75%	2.58M	$563.74M
10	Morgan Stanley	1.63%	2.41M	$526.86M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for BIIB

Google News Sat, 05 Sep 2026

BIIB Stock Price Prediction 2026-2027 | Biogen Forecast - 24/7 Wall St.

<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTE1MR3Nzd09YNTRKY3Nldm1oeTg4MGVaVHJrNWtIZENvbkFQMl93TmZGQ0pCd2EzUThoQW5IMWxHN3REOElrbTExYXI1aW9ZYTZvUFNaSzBqRkxYaHR3REItY1FHMG0?oc=5" target="_blank">BIIB Stock Price Prediction 2026…

Google News Sun, 06 Sep 2026

BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study - Stocktwits

<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxNUW5YYnVkd1N5Ynd6UG44SXA3aHVIYm5vRnlhUDN1ZFM5bnE0Wkszam5YLUktT0JBNC1LN25OeWhEY085RXlJLW1uM3NBcnJJRWxqTjVXdFBnd1RiREhneGdRY2JIMjRlZE5rbXVsWTBiMlZXb19qbG5MZ2lnSDg0V1kyTVBSeWdQSC1mOT…

Google News hu, 03 Sep 2026

Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPcXc3Y2E5Vnc5QkFmN2Zzb2RyZmVVMXAzMkZUeWFGaGUxU1V5OU45dXBwM2Utc2R6ZHpHOVI4OVVXMUFQS29zYVNZQ1BWVXgwNFBIaE4tZGtFeGFGb00tVXUtVXhfZkhwQXpnS0wtYURFYUNMeWxuaE0weEotSURzNTZON2p6QnlGQzB4Nl…

Google News Fri, 14 Aug 2026

Biogen Stock (BIIB) Opinions on Analyst Upgrade and Acquisition - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQdWQwT2dPcUtVNXg2WE5iRl9lVnZJa0UwdDcxQ0Y4OTdCTkdSNThFcUxaVWFKcFRKaHVqMTRJbnRQQzVnQ0pGZzN6SnJDa3h1bElrSmtCOUhaN1lzS0RtVmNHVldaVGlhdV9LVi1XNnIxOEoxZG0tdGlGX0ZXVWFMSmdqY2dEcl9lYjJ0ej…

Google News hu, 03 Sep 2026

Up to 20% of children with Dravet syndrome die before adulthood. A long-term study of an experimental drug showed fewer severe seizures. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPckhqNzJZaUpGWUZLVzlFNmk4Z1A2X01JNHB0VHVmNDloM0pLcHgxcm5wV21aM3NlT2U2Q0VQd1pVUkJyRWtEM19HakI1WDFSQkR5Y012akRDSTFkLXoycnJrM1lnN2hRNkw3SXp2Z2ZJY1NnUEhvYktUTVBKcUoxVGFQbnJTT3pwcGdSbn…

Google News Fri, 04 Sep 2026

Biogen (BIIB), Why Is Its Latest Update Drawing Fresh Attention? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQbDMtbGJCUFVLc0ItbHFXZVhEVy1sVnJuckRpejl3N3pJUkN1dDFMWXlZT1JvVzc5Vjd4SEVkNmZfVVVmYVp0eEVkMFFPTDNlVFhlYUNfS0o4VXV4elJOMGpaWk9EVTVZdnpWWXFhOFlsQ0ZTU1F2Y2MyZXpkNHBVcm0wTVV3QjZ1NDdVZl…

BIIB — Frequently Asked Questions

What is the current share price of Biogen Inc. (BIIB)?

As of 2026-09-07 16:24 PDT, Biogen Inc. (BIIB) trades at $220.83 on NasdaqGS. Its 52-week range is $132.22 to $224.51.

What is the market capitalisation of BIIB?

Biogen Inc. (BIIB) has a market capitalisation of $32.63B on NasdaqGS.

What is the P/E ratio of BIIB?

BIIB trades at a trailing price-to-earnings (P/E) ratio of 39.22. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.63.

What is the return on equity (ROE) of BIIB?

BIIB has a return on equity (ROE) of 4.58%. Its return on capital employed (ROCE) is 10.89%.

Is BIIB a good stock to buy?

This page provides a data-driven analysis of Biogen Inc. (BIIB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Biogen Inc. BIIB NDXSPXR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

BIIB Stock Price Prediction 2026-2027 | Biogen Forecast - 24/7 Wall St.

BIIB Stock On Track For Worst Day In 2 Years After RBC Questions If Alzheimer’s Drug Benefits Will Replicate In Further Study - Stocktwits

Biogen (BIIB) Stock Could Be 48% Below Fair Value On New Dravet Data - Yahoo Finance

Biogen Stock (BIIB) Opinions on Analyst Upgrade and Acquisition - quiverquant.com

Up to 20% of children with Dravet syndrome die before adulthood. A long-term study of an experimental drug showed fewer severe seizures. - Stock Titan

Biogen (BIIB), Why Is Its Latest Update Drawing Fresh Attention? - simplywall.st

BIIB — Frequently Asked Questions

What is the current share price of Biogen Inc. (BIIB)?

What is the market capitalisation of BIIB?

What is the P/E ratio of BIIB?

What is the return on equity (ROE) of BIIB?

Is BIIB a good stock to buy?

Explore More